Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Immunotherapy drug nivolumab takes on rare childhood and adult lymphoma

NCT ID NCT03703050

First seen Apr 24, 2026 · Last updated May 24, 2026 · Updated 3 times

Summary

This study tests the immunotherapy drug nivolumab in children and adults with a rare type of lymphoma (ALK+ anaplastic large cell lymphoma) that has come back or not responded to standard treatment. The trial has two groups: one for people with active disease to see if the drug shrinks tumors, and another for those already in remission after a relapse to see if it helps keep the cancer away. About 45 participants will receive nivolumab alone, and the goal is to measure how well the cancer responds or how long it stays gone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING/REFRACTORY ALK+ ANAPLASTIC LARGE CELL LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHU Bordeaux

    Bordeaux, France

  • CHU Bordeaux Hopital Pellegrin

    Bordeaux, 33076, France

  • CHU Mondor

    Créteil, France

  • CHU Toulouse Hopital des enfants

    Toulouse, 31059, France

  • CHU de nancy

    Vandœuvre-lès-Nancy, 54500, France

  • Centre Léon Berard Lyon

    Lyon, 69008, France

  • Centre Oscar Lambret

    Lille, France

  • Gustave Roussy

    Villejuif, Val de Marne, 94805, France

  • Hôpital Saint Louis

    Paris, 75010, France

  • Hôpital Trousseau

    Paris, Paris, 75012, France

  • IUC Toulouse

    Toulouse, 31059, France

  • Rigshospitalet

    Copenhagen, Denmark

  • Women'S and Children'S Nhs Foundation Trust

    Birmingham, United Kingdom

Conditions

Explore the condition pages connected to this study.